Product Information
ZAFIRLUKAST 20 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.6234 per EA under NDC 64380018801. Its NADAC has been published 214 times since Aug 31, 2022.
FDA first approved this application on Sep 26, 1996. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380018801
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ZAFIRLUKASTApproval Type
New Drug (NDA)
FDA Application
NDA020547FDA Approved
9/26/1996
TE Code
AB
On Market Since
8/1/2022
Pharmacological Classes
Price Statistics
The NADAC for ZAFIRLUKAST 20 MG TABLET has been published 214 times since Aug 31, 2022, and over the history we have for it it has declined 25.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6234 per EA |
|---|---|
| All-time high | $0.9991 (Dec 13, 2023) |
| All-time low | $0.4512 (Nov 20, 2024) |
| 52-week high | $0.6852 |
| 52-week low | $0.6234 |
| Median price | $0.6852 |
| Average price | $0.7310 |
| Largest weekly change | -33.6% (Nov 20, 2024) |
| Weeks tracked | 214 |
| Tracking since | Aug 31, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the zafirlukast market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
zafirlukast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukotriene Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZAFIRLUKAST 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ZAFIRLUKAST 20 MG TABLET, manufactured by Strides Pharma Inc., is $0.6234 per EA (NDC 64380018801), effective Sep 30, 2026.
How has the price of ZAFIRLUKAST 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for ZAFIRLUKAST 20 MG TABLET has declined 25.8%. It has been tracked across 214 weekly CMS publications since Aug 31, 2022.
What are the highest and lowest recorded NADAC prices for ZAFIRLUKAST 20 MG TABLET?
Since Aug 31, 2022, the NADAC for ZAFIRLUKAST 20 MG TABLET has ranged from a low of $0.4512 (Nov 20, 2024) to a high of $0.9991 (Dec 13, 2023), with a median of $0.6852 per EA.
Are there cheaper alternatives to ZAFIRLUKAST 20 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ZAFIRLUKAST 20 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZAFIRLUKAST 20 MG TABLET?
ZAFIRLUKAST 20 MG TABLET (NDC 64380018801) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.